Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter, Randomized Controlled Phase III Clinical Trial of Primary Tumor Resection in Patients With Oligometastatic EGFR-Mutant Non-Small Cell Lung Cancer After EGFR-Targeted Therapy

NCT07738172 is registered in ClinicalTrials.gov with National Taiwan University Hospital as lead sponsor.

NCT NCT07738172
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07738172 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter, Randomized Controlled Phase III Clinical Trial of Primary Tumor Resection in Patients With Oligometastatic EGFR-Mutant Non-Small Cell Lung Cancer After EGFR-Targeted Therapy
Lead sponsor
National Taiwan University Hospital
Phase
Phase 3
Overall status
Recruiting
Start date
September 8, 2026
Completion date
August 1, 2031
Enrollment
154 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

lung neoplasms, non-small cell lung cancer